Skip to main content

Table 2 Comparison of the survival rates of patients with hepatocellular carcinoma in this study versus the survival rates of patients in the original SNACOR study

From: Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

SNACOR, 3 subgroups

Low risk, 0–2 points

Intermediate risk, 3–6 points

High risk, 7–10 points

P-value

This study: median OS (95% CI), m

31.5 (23.1–46.0)

19.9 (17.1–26.2)

9.2 (6.2–21.7)

< 0.001

Original SNACOR study: median OS (95% CI), m

49.8 (34.3–65.3)

30.7 (25.8–35.6)

12.4 (5.9–18.9)

< 0.001